🔗 Share this article

Treasury head Rachel Reeves has announced she is preparing "focused steps to tackle household expense issues" in next month's Budget.

Speaking to media outlets, she stated that curbing price rises is a collective duty of both the administration and the Bank of England.

The UK's price growth is forecast to be the most elevated among the Group of Seven advanced economies this calendar year and the following year.

Potential Utility Bill Measures

Sources suggest the government could intervene to bring down energy bills, for instance by reducing the current 5% level of VAT charged on energy.

A further possibility is to lower some of the policy costs presently added to bills.

Fiscal Limitations and Analyst Expectations

The government will obtain the next assessment from the official forecaster, the Office for Budget Responsibility, on Monday, which will clarify how much space there is for these measures.

The expectation from most experts is that the Chancellor will have to introduce tax increases or budget cuts in order to adhere to her declared debt limits.

Previously on the same day, estimates indicated there was a £22bn shortfall for the Treasury chief to resolve, which is at the lower end of expectations.

"It is a collective job between the central bank and the administration to bear down further on some of the causes of price increases," the Chancellor told reporters in the US capital, at the yearly gatherings of the International Monetary Fund and World Bank.

Revenue Commitments and Global Issues

While much of the attention has been on expected tax rises, the Treasury chief said the most recent figures from the fiscal watchdog had not changed her vow to election pledges not to raise tax levels on income tax, sales tax or social security contributions.

She attributed an "uncertain world" with increasing geopolitical and trade concerns for the fiscal revenue measures, probably to be targeted on those "most able to pay."

International Economic Tensions

Commenting on worries about the UK's economic relations with China she said: "Our security interests always come first."

Last week's declaration by China to tighten export controls on rare earths and other materials that are essential for advanced tech manufacturing led US President Donald Trump to threaten an additional 100% tariff on imports from the Asian country, increasing the possibility of an full-scale commercial conflict between the two global powers.

The US Treasury Secretary described the Chinese action "commercial pressure" and "a international production control attempt."

Inquired about accepting the American proposal to join its conflict with the Asian nation, the Chancellor said she was "extremely troubled" by China's measures and called on the Chinese government "not to put up barriers and restrict access."

She said the action was "harmful for the international commerce and causes additional challenges."

"In my view there are sectors where we need to confront Chinese policies, but there are also significant chances to trade with Chinese markets, including banking sector and other areas of the economic system. We've got to achieve that equilibrium correct."

The chancellor also stated she was working with international partners "on our own essential resources strategy, so that we are reduced dependence."

Health Service Drug Pricing and Funding

The Chancellor also admitted that the cost the National Health Service spends on pharmaceuticals could go up as a result of current negotiations with the US government and its drugs companies, in return for reduced taxes and capital.

Some of the world's largest pharmaceutical manufacturers have said in recent statements that they are either pausing or scrapping operations in the UK, with several attributing the modest returns they are obtaining.

Recently, the Science Minister said the price the health service pays for medicines would must go up to halt companies and pharmaceutical investment departing from the United Kingdom.

The Chancellor told the BBC: "It has been observed as a result of the payment system, that drug testing, recent pharmaceuticals have not been provided in the United Kingdom in the extent that they are in other European countries."

"Our aim is to ensure that patients getting care from the NHS are able to access the top critical medicines in the globe. And so we are reviewing this situation, and... seeking to attract additional investment into the UK."